ArticleMedical care2016
Trends in the Treatment of Metastatic Colon and Rectal Cancer in Elderly Patients.
Article in Medical care, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Financial Hardships Experienced by Cancer Survivors: A Systematic Review.Journal of the National Cancer Institute · 2017Pooled it
- Assessing the relationship between toxicity and economic cost of oncological target agents: A systematic review of clinical trials.PloS one · 2017Pooled it
- Health care cost trajectories among patients with cancer and cardiometabolic comorbidities over a decade including the pandemic period.Journal of managed care & specialty pharmacy · 2026Article
- Cetuximab scFv-modified 5-FU Loaded Chitosan Nanoparticles: A Novel Therapeutic Platform.Current pharmaceutical biotechnology · 2026Article
- Survival benefits of immunotherapy combined with chemoradiotherapy in metastatic colorectal cancer: an analysis based on data from the SEER database.Open medicine (Warsaw, Poland) · 2026Article
- Development and validation of FinTox: A new screening tool to assess cancer-related financial toxicity.Cancer medicine · 2024Article
- Importance of Patient Health Insurance Coverage and Out-of-Pocket Costs for Genomic Testing in Oncologists' Treatment Decisions.JCO oncology practice · 2024Article
- Management of Older Adults With Colorectal Cancer: The Role of Geriatric Assessment.Clinical colorectal cancer · 2023Review
- Association of Employment Disruptions and Financial Hardship Among Individuals Diagnosed with Cancer in the United States: Findings from a Nationally Representative Study.Cancer research communications · 2023Article
- High out‑of‑pocket spending and financial hardship at the end of life among cancer survivors and their families.Israel journal of health policy research · 2023Article
- Association of Age With Treatment-Related Adverse Events and Survival in Patients With Metastatic Colorectal Cancer.JAMA network open · 2023Article
- Factors Associated with the Decision to Decline Chemotherapy in Metastatic Non-Small Cell Lung Cancer.Cancers · 2023Article
- Financial Hardship in Adult Survivors of Childhood Cancer in the Era After Implementation of the Affordable Care Act: A Report From the Childhood Cancer Survivor Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Article
- Financial toxicity among older cancer survivors in China: a qualitative study of oncology providers' perceptions and practices.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022Article
- Cancer-Related Care Costs and Employment Disruption: Recommendations to Reduce Patient Economic Burden as Part of Cancer Care Delivery.Journal of the National Cancer Institute. Monographs · 2022Article
- Treating the Whole Patient With Cancer: The Critical Importance of Understanding and Addressing the Trajectory of Medical Financial Hardship.Journal of the National Cancer Institute · 2022Article
- Greater uptake, an alternative reimbursement methodology needed to realize cost-saving potential of oncology biosimilars in the United States.Journal of managed care & specialty pharmacy · 2021Article
- Delivery of Financial Navigation Services Within National Cancer Institute-Designated Cancer Centers.JNCI cancer spectrum · 2021Article
- Current Treatment Approaches and Outcomes in the Management of Rectal Cancer Above the Age of 80.Current oncology (Toronto, Ont.) · 2021Article
- NDC1 is a Prognostic Biomarker and Associated with Immune Infiltrates in Colon Cancer.International journal of general medicine · 2021Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
6 authors.
Funding
Abstract
backgroundLittle is known about the use and costs of antineoplastic regimens for elderly patients with metastatic colorectal cancer (mCRC). We report population-based trends over a 10-year period in the treatment, survival, and costs in mCRC patients, stratified by ages 65-74 and 75+.
methodsWe used Surveillance, Epidemiology, and End Results-Medicare data for persons diagnosed with metastatic colon (N=16117) or rectal cancer (N=4008) between 2000 and 2009. We estimated the adjusted percent of patients who received antineoplastic agents, by type, number, and their costs 12 months following diagnosis. We report the percent of patients who received 3 or more of commonly prescribed agents and estimate survival for the 24-month period following diagnosis by age and treatment.
resultsThe percentage that received 3 or more agents increased from 3% to 73% in colon patients aged 65-74 and from 2% to 53% in patients 75+. Similar increases were observed in rectal patients. Average 1-year costs per patient in 2009 were $106,461 and $102,680 for colon and rectal cancers, respectively, reflecting an increase of 32% and 20%, for patients who received antineoplastic agents. Median survival increased by about 6 and 10 months, respectively, for colon and rectal patients aged 65-74 who received antineoplastic agents, but an improvement of only 1 month of median survival was observed for patients 75+.
conclusionsExpensive multiple agent regimens are increasingly used in older mCRC patients. For patients aged 64-75 years, these treatments may be associated with several months of additional life, but patients aged 75+ may incur considerable expense without any survival benefit.
Indexed as
Identifiers
26900834What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.